148 related articles for article (PubMed ID: 9389851)
41. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
Broman M; Islander G; Müller CR; Ranklev-Twetman E
Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
[TBL] [Abstract][Full Text] [Related]
42. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
Wehner M; Rueffert H; Koenig F; Olthoff D
Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
[TBL] [Abstract][Full Text] [Related]
43. Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.
Kaufmann A; Kraft B; Michalek-Sauberer A; Weindlmayr M; Kress HG; Steinboeck F; Weigl LG
Anesth Analg; 2012 May; 114(5):1017-25. PubMed ID: 22415532
[TBL] [Abstract][Full Text] [Related]
44. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
Heytens L
Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
[TBL] [Abstract][Full Text] [Related]
45. The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree.
Adeokun AM; West SP; Ellis FR; Halsall PJ; Hopkins PM; Foroughmand AM; Iles DE; Robinson RL; Stewart AD; Curran JL
Am J Hum Genet; 1997 Apr; 60(4):833-41. PubMed ID: 9106529
[TBL] [Abstract][Full Text] [Related]
46. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.
Manning BM; Quane KA; Ording H; Urwyler A; Tegazzin V; Lehane M; O'Halloran J; Hartung E; Giblin LM; Lynch PJ; Vaughan P; Censier K; Bendixen D; Comi G; Heytens L; Monsieurs K; Fagerlund T; Wolz W; Heffron JJ; Muller CR; McCarthy TV
Am J Hum Genet; 1998 Mar; 62(3):599-609. PubMed ID: 9497245
[TBL] [Abstract][Full Text] [Related]
47. [Molecular pathology of malignant hyperthermia and central core disease].
Takagi A
Nihon Rinsho; 1997 Dec; 55(12):3307-14. PubMed ID: 9436456
[TBL] [Abstract][Full Text] [Related]
48. Malignant hyperthermia and excitation-contraction coupling.
Melzer W; Dietze B
Acta Physiol Scand; 2001 Mar; 171(3):367-78. PubMed ID: 11412150
[TBL] [Abstract][Full Text] [Related]
49. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
[TBL] [Abstract][Full Text] [Related]
50. Novel ryanodine receptor mutation that may cause malignant hyperthermia.
Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG
Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443
[TBL] [Abstract][Full Text] [Related]
51. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.
Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V
Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904
[TBL] [Abstract][Full Text] [Related]
52. Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.
Moroni I; Gonano EF; Comi GP; Tegazzin V; Prelle A; Bordoni A; Bresolin N; Scarlato G
J Neurol; 1995 Feb; 242(3):127-33. PubMed ID: 7751854
[TBL] [Abstract][Full Text] [Related]
53. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia.
Quane KA; Healy JM; Keating KE; Manning BM; Couch FJ; Palmucci LM; Doriguzzi C; Fagerlund TH; Berg K; Ording H
Nat Genet; 1993 Sep; 5(1):51-5. PubMed ID: 8220423
[TBL] [Abstract][Full Text] [Related]
54. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
[TBL] [Abstract][Full Text] [Related]
55. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
[TBL] [Abstract][Full Text] [Related]
56. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
[TBL] [Abstract][Full Text] [Related]
57. A mutation in the human ryanodine receptor gene associated with central core disease.
Zhang Y; Chen HS; Khanna VK; De Leon S; Phillips MS; Schappert K; Britt BA; Browell AK; MacLennan DH
Nat Genet; 1993 Sep; 5(1):46-50. PubMed ID: 8220422
[TBL] [Abstract][Full Text] [Related]
58. RYR mutation G1021A (Gly341Arg) is not frequent in Danish and Swedish families with malignant hyperthermia susceptibility.
Fagerlund T; Ording H; Bendixen D; Islander G; Ranklev-Twetman E; Berg K
Clin Genet; 1996 Apr; 49(4):186-8. PubMed ID: 8828983
[TBL] [Abstract][Full Text] [Related]
59. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility.
Deufel T; Golla A; Iles D; Meindl A; Meitinger T; Schindelhauer D; DeVries A; Pongratz D; MacLennan DH; Johnson KJ
Am J Hum Genet; 1992 Jun; 50(6):1151-61. PubMed ID: 1598899
[TBL] [Abstract][Full Text] [Related]
60. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots.
Gillies RL; Bjorksten AR; Davis M; Du Sart D
Anaesth Intensive Care; 2008 May; 36(3):391-403. PubMed ID: 18564801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
